We advised the joint book-running managers and underwriters on the IPO and Nasdaq listing

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $297 million initial public offering by Immunocore Holdings plc of 11,426,280 American Depositary Shares (“ADSs”), each representing one ordinary share, which includes 1,490,384 ADSs from the full exercise of the underwriters’ over-allotment option to purchase additional ADSs. The ADSs are listed on the Nasdaq Global Select Market under the symbol “IMCR.”

Headquartered in Oxfordshire, United Kingdom, Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune. To date, it has dosed over 600 cancer patients with its product candidates.

The Davis Polk capital markets team included partners Yasin Keshvargar and Richard D. Truesdell Jr. and associates Daniel Chao and Jordyn Giannone. Partner Simon Witty and associate Mark Chalmers provided English law advice. Partner David R. Bauer and associates Hilary Smith provided intellectual property advice. The UK and US tax teams included partner Jonathan Cooklin and counsel Kiara L. Rankin.Members of the Davis Polk team are based in the New York and London offices.

Copy link to share post